In comparison, a randomised controlled trial in 1,961 people showed that 69% of participants on Wegovy achieved more than 10% weight loss, with 50% achieving more than 15%
These results inform clinical decision-making and expand knowledge of incretin-based therapys broader health benefits
Does It Work?, April 23, 2024 Yale Medicine, GLP-1 Agonists: Wonder Drugs of the 21st Century?, July 2, 2024 Drugs, Wegovy (semaglutide) FDA Approval History, April 2, 2026 Food and Drug Administration, FDA approves weight management drug for patients aged 12 and older, Dec
Moreover, this enhanced the accessibility of the drugs
It is important to note that these dosages are general recommendations and can be adjusted based on individual factors, such as medical condition(s), treatment response, and tolerability